Nucala 100 MG/ML auto-injectorml
Ended Awarded
- Contract number
- SPE2DB26FNMNQ
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,893
Award facts
- Contract value 100% obligated
- $1,892.90 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,892.90 to DMS Pharmaceutical Group Inc. on November 4, 2025, for the supply of Nucala 100 mg/ml auto-injector units. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The delivery order is classified as firm fixed-price and carries an ultimate completion date of November 5, 2025, with performance to be executed at the vendor's Park Ridge, Illinois location.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the DLA Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical supply to Department of Defense healthcare facilities worldwide. The parent IDC, valued at $499.999 billion with a completion date of December 31, 2036, authorizes DLA to issue firm fixed-price delivery orders for comprehensive pharmaceutical products including branded and generic prescription medications, biologics, and medical consumables. DMS Pharmaceutical Group has demonstrated substantial performance capability through numerous prior delivery orders across diverse therapeutic categories, positioning it as a critical supplier within the federal military medical supply chain.
Quick answers
Who was awarded contract SPE2DB26FNMNQ?
SPE2DB26FNMNQ was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 4, 2025.
How much is contract SPE2DB26FNMNQ worth?
The government has obligated $1,893 on SPE2DB26FNMNQ.
Is contract SPE2DB26FNMNQ an order under another contract?
Yes. SPE2DB26FNMNQ is a delivery order under SPE2DB25D9348, an indefinite delivery contract.
Was contract SPE2DB26FNMNQ competed?
The extent of competition for SPE2DB26FNMNQ was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award